MK-677 (Ibutamoren) and Tadalafil Interaction

Why This Combination Raises Questions

Men using tadalafil for erectile dysfunction or benign prostatic hyperplasia (BPH) sometimes add MK-677 to increase growth hormone (GH) secretion, with goals ranging from body composition improvement to anti-aging effects. The combination has gained traction in online forums despite a near-total absence of co-administration data in controlled trials.

MK-677 (ibutamoren mesylate) is a non-peptide ghrelin receptor agonist that stimulates pulsatile GH release from the anterior pituitary [1]. It was studied in several Phase II trials during the late 1990s and 2000s but never received FDA approval. Tadalafil, by contrast, is an FDA-approved phosphodiesterase type 5 (PDE5) inhibitor with well-characterized pharmacokinetics and a 17.5-hour half-life [2]. The absence of co-administration studies means clinicians must reason from first principles: shared metabolic pathways, overlapping side-effect profiles, and individual pharmacodynamic effects.

No case reports of a serious adverse event from this specific pair appear in PubMed or the FDA Adverse Event Reporting System (FAERS) as of May 2026. That absence is not the same as a safety guarantee. It reflects the fact that MK-677 sits outside the regulated pharmaceutical supply chain in most countries.

CYP3A4 Metabolism: Shared Pathway, Low Conflict

Both MK-677 and tadalafil are substrates of cytochrome P450 3A4 (CYP3A4), the liver enzyme responsible for metabolizing roughly 50% of all marketed drugs. This shared pathway is the most commonly cited concern, but context matters.

Tadalafil's prescribing information identifies CYP3A4 as its primary metabolic route, and the label warns against co-administration with strong CYP3A4 inhibitors such as ketoconazole and ritonavir, which increase tadalafil AUC by 312% and 124%, respectively [2]. MK-677 has not been classified as a CYP3A4 inhibitor or inducer in the published pharmacokinetic literature. Early Phase I data from Merck showed linear pharmacokinetics at doses up to 25 mg with no evidence of auto-inhibition of its own CYP3A4-mediated clearance [3].

Two CYP3A4 substrates taken together do not automatically produce a clinically meaningful interaction. Competition for the same enzyme binding site could theoretically slow the metabolism of one or both compounds, but this effect tends to be minor unless one agent is present at concentrations high enough to saturate the enzyme. At the commonly reported dose of MK-677 (10-25 mg/day), plasma concentrations remain well below the threshold needed for competitive inhibition of CYP3A4 based on available preclinical data [3].

The practical takeaway: a strong CYP3A4 inhibitor like ketoconazole poses a real risk with tadalafil. MK-677 does not fall into that category.

Pharmacodynamic Overlap: Where the Real Risks Live

The more relevant clinical concern is pharmacodynamic, not pharmacokinetic. Both compounds independently affect blood pressure, fluid balance, and metabolic parameters.

Blood pressure. Tadalafil produces a mild systolic blood pressure reduction of approximately 1.6 mmHg in normotensive men and slightly more in hypertensive patients [4]. MK-677, through its GH and IGF-1-elevating effects, can cause sodium and water retention. In a 12-month trial of 65 older adults given MK-677 25 mg/day, Nass et al. (2008) reported increases in weight (predominantly lean mass and water) along with a small but measurable rise in fasting glucose [1]. Blood pressure increases were not statistically significant in that trial, but individual patients did develop ankle edema requiring dose reduction.

The directional opposition of these effects (tadalafil lowering BP, MK-677 potentially raising it through volume expansion) does not cancel out neatly. A patient with borderline hypertension could experience unpredictable BP fluctuations.

Fluid retention and edema. This is the most concrete overlap. Tadalafil's label lists peripheral edema among reported adverse events, particularly at the 40 mg dose used for pulmonary arterial hypertension [2]. MK-677 reliably increases extracellular water volume. Svensson et al. (1998) documented a 2.7 kg weight gain over 8 weeks in obese subjects on MK-677 25 mg/day, with a significant portion attributable to water retention [5]. Combining both agents in a patient prone to fluid overload (heart failure, chronic kidney disease, or on concurrent amlodipine) could push edema from cosmetic annoyance to clinical problem.

Insulin and Glucose: A Metabolic Consideration

MK-677 consistently raises fasting blood glucose and can reduce insulin sensitivity. This effect has been documented across multiple trials.

In the Nass et al. (2008) study (N=65, healthy adults aged 60-81), MK-677 25 mg/day for 12 months increased fasting glucose by approximately 0.3 mmol/L (roughly 5 mg/dL) and raised HbA1c from 5.7% to 5.9% in the treatment group [1]. Several participants developed fasting glucose values in the impaired fasting glucose (IFG) range. A separate 2-month study by Svensson et al. confirmed elevated fasting insulin levels, consistent with reduced peripheral insulin sensitivity [5].

Tadalafil does not directly affect glucose metabolism. However, men seeking both compounds often fall into demographics with pre-existing metabolic risk: age over 40, overweight, sedentary lifestyle. The addition of MK-677 to this profile could unmask latent insulin resistance.

A practical screening framework: before concurrent use, check fasting glucose, HbA1c, and a basic metabolic panel. Recheck at 4 weeks and 12 weeks. Any fasting glucose reading above 110 mg/dL should prompt reconsideration of MK-677 dosing or discontinuation.

What About IGF-1 and Cardiovascular Risk?

MK-677 raises IGF-1 levels. This is its intended pharmacologic effect. But elevated IGF-1 carries its own set of concerns, particularly for cardiovascular health and cancer risk in long-term use.

In the Nass et al. trial, MK-677 increased IGF-1 levels to the upper quartile of the young-adult reference range within 2 weeks and maintained that elevation for 12 months [1]. The Endocrine Society's 2011 clinical practice guideline on GH deficiency in adults notes that IGF-1 should be monitored and kept below the age-adjusted upper limit of normal to reduce theoretical risks [6]. Sustained supraphysiologic IGF-1 has been associated with increased risk of colorectal and prostate cancer in epidemiologic studies, though causality remains debated [7].

Tadalafil does not affect the GH-IGF-1 axis. The interaction concern here is indirect: a man using tadalafil for BPH who adds MK-677 for body composition may not realize that chronically elevated IGF-1 could be a confounding factor in prostate health surveillance. PSA interpretation becomes more complex when IGF-1 is elevated.

Clinicians managing this combination should monitor IGF-1 levels every 3 months and target values within the age-appropriate reference range, not the upper quartile of a 25-year-old.

Nitrate Interaction: Not a Shared Risk, but Worth Clarifying

One of the most dangerous drug interactions with tadalafil involves organic nitrates (nitroglycerin, isosorbide mononitrate). Co-administration can cause severe, potentially fatal hypotension. The tadalafil prescribing information carries a black-box-level contraindication against nitrate use [2].

MK-677 is not a nitrate. It does not donate nitric oxide or potentiate the cGMP pathway. There is no mechanistic basis for a nitrate-type hypotensive crisis when MK-677 is combined with tadalafil. This distinction matters because online forums sometimes conflate "blood pressure concern" with "nitrate-like danger." They are categorically different risks.

The blood pressure concern with MK-677 and tadalafil is one of mild, chronic hemodynamic variability, not acute cardiovascular collapse.

Timing and Dose Considerations

Tadalafil's 17.5-hour half-life means it remains pharmacologically active for well over a day after a single dose. The daily dosing regimen (2.5 mg or 5 mg for BPH/ED) produces steady-state concentrations by day 5 [2]. MK-677 also has a long duration of action: a single 25 mg oral dose elevates GH pulsatility for approximately 24 hours, and IGF-1 elevation persists for days [1].

Separating doses by a few hours (a common forum recommendation) does not meaningfully reduce pharmacodynamic overlap given these long half-lives. Both compounds will be active simultaneously regardless of timing within a 24-hour cycle.

More relevant than timing is dose selection. The most commonly studied MK-677 dose in clinical trials was 25 mg/day, but lower doses (10 mg) were also evaluated by Murphy et al. (1998) and produced GH elevation with fewer side effects [3]. For patients set on concurrent use, starting MK-677 at 10 mg/day while on stable tadalafil therapy, then reassessing at 4 weeks, represents a more cautious approach than jumping to 25 mg.

Monitoring Protocol for Concurrent Use

Because no regulatory body has evaluated this combination, any monitoring protocol is based on the individual adverse-effect profiles of each drug and clinical judgment.

Baseline (before adding MK-677 to tadalafil therapy):

• Fasting glucose and HbA1c
• Complete metabolic panel including electrolytes and creatinine
• Blood pressure (seated, two readings 5 minutes apart)
• IGF-1 level
• Body weight and assessment of peripheral edema

At 4 weeks:

• Repeat fasting glucose, blood pressure, weight, and edema check
• If fasting glucose has risen above 110 mg/dL or edema has developed, reduce MK-677 dose or discontinue

At 12 weeks and quarterly thereafter:

• IGF-1 level (target: within age-adjusted reference range)
• HbA1c
• Blood pressure
• For men over 50: PSA, given the theoretical interaction between elevated IGF-1 and prostate tissue growth

This schedule is not derived from a clinical trial. It reflects the minimum monitoring that the individual risk profiles of these two compounds would warrant when used together.

Regulatory Status and Supply Chain Risk

MK-677 is not FDA-approved. It is not a dietary supplement. The FDA has issued warning letters to companies marketing products containing ibutamoren as dietary supplements, and the compound is banned by the World Anti-Doping Agency (WADA) under the S2 category (peptide hormones, growth factors, and mimetics) [8].

Products sold online as "MK-677" may contain inconsistent doses, contaminants, or different compounds entirely. A 2020 analysis of research peptide vendors found that label accuracy for non-FDA-approved compounds varied widely, with some products containing less than 50% of the stated dose [9]. This uncertainty compounds any drug interaction risk. A patient who believes they are taking 10 mg of MK-677 may be taking 5 mg or 20 mg, making dose-dependent side effects unpredictable.

Tadalafil, by contrast, is available as a regulated generic with consistent bioequivalence data. The interaction risk assessment in this article assumes pharmaceutical-grade MK-677 at stated doses, a condition that cannot be guaranteed with gray-market products.

When to Avoid This Combination Entirely

Certain patient populations should not combine these agents:

• Heart failure (any class): The fluid retention from MK-677 can worsen volume overload. Tadalafil is approved for pulmonary arterial hypertension but is used at higher doses (40 mg) in that setting, increasing edema risk.
• Type 2 diabetes or prediabetes (HbA1c ≥5.7%): MK-677's glucose-raising effect may push a borderline patient into diabetic range.
• Concurrent use of alpha-blockers or antihypertensives: Tadalafil combined with alpha-blockers (tamsulosin, doxazosin) already carries a hypotension advisory [2]. Adding MK-677's fluid-retention effects creates a less predictable hemodynamic profile.
• Active cancer or cancer surveillance: Elevated IGF-1 is a concern in patients with a history of prostate, colorectal, or breast cancer.

For men without these contraindications who choose to use both compounds, the combination does not appear to carry a high-severity pharmacokinetic interaction risk. The pharmacodynamic concerns (edema, glucose, IGF-1 elevation) are manageable with monitoring but require active clinical follow-up rather than passive self-administration.

Fasting glucose above 126 mg/dL, new peripheral edema, or IGF-1 above the age-adjusted upper limit at any follow-up visit should trigger MK-677 dose reduction or discontinuation regardless of subjective benefit.